Hypoglycemia
Drug research and approvals for hypoglycemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 70 studies of hypoglycemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, and FDA has 1 approved and 6 open orphan designations naming it.
- Recruiting worldwide: 70
- Trials authorized in Canada: 4
- FDA orphan approvals: 1
- EU medicines: 0
- Post-Prandial Carbohydrate Metabolism in Individuals With and Without Post-Bariatric Surgery Hypoglycemia (PBH)NCT07818707 · Phase 4 · Joslin Diabetes Center · starts Jan 27, 2026
- Changes in Person-reported Outcomes and Behavior Using the Accu-Chek SmartGuide CGM and Predict AppNCT07814508 · Not applicable · FIDAM RDC · starts Feb 1, 2026
- Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric HypoglycemiaNCT07760961 · Phase 2 · Vogenx, Inc. · starts Oct 20, 2026
- Comparison of Hormonal Response to a Mixed-Meal Tolerance Test After Laparoscopic Roux-en-Y Gastric Bypass Versus…NCT07747779 · Not applicable · Chulalongkorn University · starts Aug 8, 2024
- GlycoQuest: An AI-Adaptive CGM-Integrated Serious Game for Pediatric Type 1 DiabetesNCT07726680 · Not applicable · Shifa International Hospital · starts Jun 1, 2026
- Miniaturized Breath-based Sensor for the Detection of Hypo- and HyperglycemiaNCT07696273 · Not applicable · Indiana University · starts May 31, 2026
- Continuous Glucose Monitoring With iCan i3 in Post-Bariatric Patients With Late Dumping SyndromeNCT07440706 · Not applicable · Kaiser Clinic and Hospital · starts Oct 15, 2025
- The Postprandial Hypo-Avoid StudyNCT07427251 · Phase 4 · Steno Diabetes Center Copenhagen · starts Apr 27, 2026
- FEAR of HYPOGLYCEMIA in PATIENTS WITH DIABETESNCT07329985 · Not reported · Bilecik Seyh Edebali Universitesi · starts Apr 15, 2026
Approved 3
- GlucagonGlucagon receptor agonist
- DiazoxidePotassium channel, inwardly rectifying, subfamily J, member 11 opener
- DonislecelSomatic cell supplemental therapy
Phase 3 2
- DasiglucagonGlucagon receptor agonist
- CanakinumabInterleukin-1 beta inhibitor
Phase 2 8
- Insulin humanInsulin receptor agonist
- Mizagliflozin
- MetoclopramideDopamine D2 receptor antagonist
- PasireotideSomatostatin receptor 5 agonist
- AnakinraInterleukin-1 receptor antagonist
- CarvedilolAdrenergic receptor beta antagonist
- EmpagliflozinSodium/glucose cotransporter 2 inhibitor
- Ersodetug
Phase 1 or earlier 12 of 15
- Insulin porkInsulin receptor agonist
- Dextrose
- MoxifloxacinTopoisomerase IV inhibitor
- GemifloxacinDNA gyrase inhibitor
- PancrelipaseFatty acids hydrolytic enzyme
- SomatostatinSomatostatin receptor agonist
- Fructose
- Avexitide acetate
- VolagidemabGlucagon receptor inhibitor
- Amylopectin
- AtropineMuscarinic acetylcholine receptor M3 antagonist
- PropranololBeta-1 adrenergic receptor antagonist
How its trials ended
599 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 150 whose ending is known, 49% met their primary endpoint, 4% missed it and 47% stopped early.
- Completed, result not reported30150%
- Ongoing9316%
- Met its primary endpoint7312%
- Status unknown559%
- Stopped: other or unclear407%
- Stopped: enrollment or feasibility132%
- Missed its primary endpoint61%
- Stopped: lack of efficacy61%
- Stopped: funding61%
- Stopped: sponsor or business decision41%
- Stopped: safety2<1%
| Aug 27, 2021 | A phase 1/2 study to evaluate the safety, tolerability, and efficacy of VX-880 in subjects who have type 1 diabetes mellitus with impaired hypoglycemic…VX-880 | Vertex Pharmaceuticals | Ongoing |
| Jan 16, 2018 | G-pen tm(glucagon injection) compared to lilly glucagon (glucagon for injection [rdna origin]) for induced hypoglycemia rescue in adult patients with T1D: a…Glucagon | Xeris Pharmaceuticals | Closed |
| Dec 1, 2017 | An open-label, first-in-human, study evaluating the safety,tolerability, and efficacy of VC-02 combination product in subjects with type 1 diabetes mellitus…VC-02 (VC-02-20, VC-02-300) | Vertex Pharmaceuticals | Ongoing |
| Oct 26, 2017 | A one-year, multicenter, non-interventional, follow-up, safety study in subjects previously implanted with VC-02 combination productVC-02 | Vertex Pharmaceuticals | Ongoing |
| Jun 28, 2023 | LantidraTreatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe… | CellTrans Inc. | Approved |
| Nov 20, 2024 | ErsodetugTreatment of hypoglycemia due to tumor-associated hyperinsulinism | Rezolute Inc. | Designated |
| Jan 24, 2018 | Glucagon (ready-to-use)Treatment of hyperinsulinemic hypoglycemia | Xeris Pharmaceuticals, Inc. | Designated |
| Aug 10, 2017 | DasiglucagonTreatment and prevention of hypoglycemia in patients with congenital hyperinsulinism | Zealand Pharma A/S | Designated |
| Dec 8, 2016 | AvexitideTreatment of hyperinsulinemic hypoglycemia | Amylyx Pharmaceuticals, Inc. | Designated |
| Sep 25, 2014 | Glucagon infusionPrevention of chronic, severe hypoglycemia related to congential hyperinsulinism | Xeris Pharmaceuticals, Inc. | Designated |
| Dec 5, 2012 | GlucagonPrevention of hypoglycemia in the congenital hyperinsulinism population | Biodel, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA